Free Trial
NASDAQ:VRDN

Viridian Therapeutics Q4 2023 Earnings Report

Viridian Therapeutics logo
$16.41 -0.12 (-0.73%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$16.43 +0.02 (+0.12%)
As of 08/8/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viridian Therapeutics EPS Results

Actual EPS
-$1.35
Consensus EPS
-$0.98
Beat/Miss
Missed by -$0.37
One Year Ago EPS
-$1.13

Viridian Therapeutics Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
$0.15 million
Beat/Miss
Missed by -$80.00 thousand
YoY Revenue Growth
-31.40%

Viridian Therapeutics Announcement Details

Quarter
Q4 2023
Time
After Market Closes
Conference Call Date
Tuesday, February 27, 2024
Conference Call Time
4:00PM ET

Viridian Therapeutics Earnings Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
See More Viridian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email.

About Viridian Therapeutics

Viridian Therapeutics (NASDAQ:VRDN), a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

View Viridian Therapeutics Profile

More Earnings Resources from MarketBeat